Slide 1: Q1 2025 Financial Results
Q1 2025 Financial Results Conference call | April 24, 2025 www.materialise.com | NASDAQ: MTLS
Slide 2: Safe Harbor Summary
Safe Harbor Summary This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections,
Slide 3: Agenda
Agenda • Q1 2025 Business Highlights • Q1 2025 Financial Highlights Brigitte de Vet-Veithen CEO • Q1 2025 Financial Results • 2025 Financial Guidance • Q&A Koen Berges CFO 3
Slide 4: Q1 2025 Business Highlights
Q1 2025 Business Highlights Sustainable growth: 32% reduction in CO2 since 2019, targetting 55% by 2029 Medical: continued strong uptake of personalized solutions • Integrated Mimics platform accelerates adoption of personalized medical care • Bioresorbable implant enters FDA clinical trial – 3D-pri
Slide 5: Q1 2025 – Financial Highlights
Q1 2025 – Financial Highlights • Revenue of 66.4 mEUR, representing an increase of 4.3% from Q1 2024 • Adjusted EBIT of 646 kEUR, representing 1.0% of revenue • Net loss of (535) kEUR, representing (1) EUR-ct. per share • Net Cash position of 67.7 mEUR, representing an increase of 6.7 mEUR over Q1 2
Slide 6: Consolidated Revenue
Q1 2025 Consolidated Revenue Q1 2025 Revenue by Segment +4.3% 66,379 15% Software 63,637 Medical 39% Manufacturing 47% Q1 2024 Q1 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Revenue of 66.4 mEUR, representing an increase of 4.3% compared to Q1 2024 • Continued d
Slide 7: Consolidated Adjusted EBIT & EBITDA
Q1 2025 Consolidated Adjusted EBIT & EBITDA 2,656 8,094 -24.1% -75.7% 6,147 4.2% 12.7% 9.3% 646 1.0% Q1 2024 Adj. EBIT Q1 2025 Q1 2024 Adj. EBITDA Q1 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q1 2025 Adjusted EBIT decreased by 76% to 646 kEUR compared to Q1 20
Slide 8: Medical Segment
Q1 2025 Medical Segment +18.7% +14.2% 31,078 9,047 26,183 7,921 29.1% 30.3% Q1 2024 Revenue Q1 2025 Q1 2024 Adj. EBITDA Q1 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q1 2025 revenue increased 19% to 31.1 mEUR • Revenue from medical software grew 14% • Revenue f
Slide 9: Software Segment
Q1 2025 Software Segment -6.4% 10,438 1,090 9,775 -45.0% 10.4% 599 6.1% Q1 2024 Revenue Q1 2025 Q1 2024 Adj. EBITDA Q1 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q1 2025 revenue decreased by 6% to 9.8 mEUR compared to Q1 2024, with 0.7 mEUR additional revenue d
Slide 10: Manufacturing Segment
Q1 2025 Manufacturing Segment -5.5% 27,016 1,529 25,526 5.7% (1.5)% Q1 2024 Revenue Q1 2025 -377 Adj. EBITDA [Data in kEUR unless notes otherwise. All numbers and percentages rounded] Q1 2024 Q1 2025 • Compared to Q1 2025 segment revenue decreased by 6% to 25.5 mEUR • Compared to Q4 2024 segment rev
Slide 11: Income Statement Highlights
Income Statement Highlights Q1 2025 Q1 2024 Gross profit margin (in %) Revenue 66,379 63,637 56.5% Cost of sales (29,654) (27,702) 55.3% Gross profit 36,724 35,935 Research & development expenses (11,414) (10,231) Q1 2024 Q1 2025 Sales & marketing expenses (15,071) (14,598) General & administrative
Slide 12: Other Financial Highlights
Other Financial Highlights Balance Sheet items 3/31/25 12/31/24 Cash flow from operations 9,970 9,713 Cash and equivalents 104,180 102,304 Borrowings 36,444 41,284 Net Cash 67,736 61,020 Q1 2024 Q1 2025 Trade receivables 49,571 53,052 Inventories 16,148 16,992 Capital expenditures (cash impact) Trad
Slide 13: 2025 Financial Guidance Update
2025 Financial Guidance Update Maintaining prior guidance for revenue and Adjusted EBIT • Expect 2025 consolidated revenue within 270 - 285 mEUR range • Expect 2025 consolidated Adjusted EBIT within 6 - 10 mEUR range 13
Slide 14: Adjusted EBIT/EBITDA Reconciliation
Appendix Adjusted EBIT/EBITDA Reconciliation [Data in kEUR unless noted otherwise. All numbers and percentages rounded] Q1 2025 Q1 2024 Net profit/(loss) (535) 3,585 Income taxes 234 510 Financial expenses 2,772 798 Financial income (1,897) (2,308) EBIT 574 2,585 Depreciation & amortization 5,501 5,
Slide 15: Thank You
Thank You Contact: Investor Relations Materialise investors@materialise.com 15